Bluefin Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.14K | Buy |
+15,200
| New | +$405K | ﹤0.01% | 120 |
|
|
2025
Q4 | – | Hold |
0
| – | – | – | 186 |
|
|
2023
Q1 | – | Sell |
-14,100
| Closed | -$9.02K | – | 405 |
|
|
2022
Q4 | $9.02K | Hold |
14,100
| – | – | ﹤0.01% | 350 |
|
|
2022
Q3 | $99K | Buy |
+14,100
| New | +$685K | 0.01% | 335 |
|
|
2022
Q2 | – | Sell |
-14,600
| Closed | -$7K | – | 694 |
|
|
2022
Q1 | $7K | Sell |
14,600
-297,800
| -95% | -$15.5M | ﹤0.01% | 586 |
|
|
2021
Q4 | $39K | Buy |
312,400
+189,700
| +155% | +$9.4M | ﹤0.01% | 710 |
|
|
2021
Q3 | $53K | Buy |
122,700
+76,700
| +167% | +$3.4M | 0.01% | 559 |
|
|
2021
Q2 | $3K | Buy |
46,000
+34,900
| +314% | +$1.36M | ﹤0.01% | 648 |
|
|
2021
Q1 | $10K | Sell |
11,100
-4,500
| -29% | -$160K | ﹤0.01% | 703 |
|
|
2020
Q4 | $3K | Buy |
+15,600
| New | +$572K | ﹤0.01% | 653 |
|
|
2020
Q3 | – | Sell |
-19,815
| Closed | -$19K | – | 540 |
|
|
2020
Q2 | $19K | Sell |
19,815
-6,535
| -25% | -$222K | ﹤0.01% | 337 |
|
|
2020
Q1 | $11K | Buy |
+26,350
| New | +$898K | ﹤0.01% | 380 |
|
|
2019
Q4 | – | Sell |
-72,515
| Closed | -$51K | – | 703 |
|
|
2019
Q3 | $51K | Buy |
+72,515
| New | +$2.64M | 0.01% | 367 |
|
|
2019
Q2 | – | Sell |
-36,047
| Closed | -$14K | – | 443 |
|
|
2019
Q1 | $14K | Buy |
+36,047
| New | +$1.44M | ﹤0.01% | 353 |
|
|
2018
Q4 | – | Sell |
-67,772
| Closed | -$34K | – | 513 |
|
|
2018
Q3 | $34K | Buy |
+67,772
| New | +$2.61M | ﹤0.01% | 415 |
|
|
2017
Q2 | – | Sell |
-112,883
| Closed | -$9K | – | 580 |
|
|
2017
Q1 | $9K | Buy |
112,883
+75,993
| +206% | +$2.4M | ﹤0.01% | 416 |
|
|
2016
Q4 | $22K | Sell |
36,890
-18,445
| -33% | -$563K | ﹤0.01% | 456 |
|
|
2016
Q3 | $10K | Sell |
55,335
-167,797
| -75% | -$5.61M | ﹤0.01% | 398 |
|
|
2016
Q2 | $23K | Buy |
223,132
+170,432
| +323% | +$5.44M | ﹤0.01% | 394 |
|
|
2016
Q1 | $38K | Sell |
52,700
-23,083
| -30% | -$659K | ﹤0.01% | 400 |
|
|
2015
Q4 | $3K | Buy |
+75,783
| New | +$2.38M | ﹤0.01% | 621 |
|
|
2014
Q4 | – | Sell |
-50,697
| Closed | -$21K | – | 854 |
|
|
2014
Q3 | $21K | Buy |
+50,697
| New | +$1.42M | ﹤0.01% | 824 |
|
|
2013
Q3 | – | Sell |
-13,353
| Closed | -$7.5M | – | 521 |
|
|
2013
Q2 | $7.5M | Buy |
+13,353
| New | +$369K | 0.7% | 31 |
|
Other funds holding PFE
VCM
VPM
Bluefin Capital Management's PFE Position: Q1 2026 in Review
Bluefin Capital Management reduced its Pfizer (PFE) stake by 45% in Q1 2026, selling an estimated $873K and leaving 39,754 shares worth $1.12M. The position accounts for 0.72% of the portfolio, ranked #28.
Bluefin Capital Management first reported a position in PFE in Q2 2013 and has held it in 40 quarters since. The position peaked at $34.4M in Q2 2013. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Bluefin Capital Management held 39,754 shares of Pfizer worth $1.12M as of Q1 2026.
- Bluefin Capital Management sold 32,788 Pfizer shares in Q1 2026, an estimated $873K.
- Pfizer made up 0.72% of Bluefin Capital Management's portfolio in Q1 2026, its #28 holding.
- Bluefin Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 40 quarters since.
- Bluefin Capital Management's Pfizer position peaked at $34.4M in Q2 2013.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Bluefin Capital Management's 13F filing for Q1 2026, filed 15 May 2026.